Peptides Containing Saccharide Radicals, E.g., Bleomycins, Etc. Patents (Class 530/322)
-
Publication number: 20130266604Abstract: Described herein is a peptide, referred to as a GlycoTag peptide, that includes repeats of an N-linked glycosylation sequon that is naturally present in C. jejuni. The GlycoTag peptide can be in a purified and isolated form following expression of a construct encoding the GlycoTag peptide or it is, in whole or in part, a synthetic peptide. The GlycoTag peptide is typically used with glycans attached thereto. The GlycoTag peptide can be used alone or in combination with different proteins or peptides and can be incorporated into a chimeric protein or peptide for use in the development of antigen/antibody delivery systems, the preparation of vaccines, pharmaceuticals and diagnostic tests, and research into therapies for countering Campylobacter and other infections.Type: ApplicationFiled: September 2, 2011Publication date: October 10, 2013Inventors: Christine Szymanski, Harald Nothaft
-
Publication number: 20130261065Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of NANOG, in particular, by targeting natural antisense polynucleotides of NANOG. The invention also related to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NANOG.Type: ApplicationFiled: November 17, 2011Publication date: October 3, 2013Inventors: Joseph Collard, Olga Khorkova Sherman
-
Publication number: 20130253168Abstract: In an embodiment the instant invention discloses a modular composition comprising 1) an oligonueleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at the 2?-position of the ribose rings and/or the terminal 3?- and/or 5?-positions of the oligonucleotide; 3) optionally, one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide.Type: ApplicationFiled: August 29, 2011Publication date: September 26, 2013Inventors: Steven L. Colletti, Francis Gosselin, Vasant R. Jadhav, Anthony W. Shaw, David M. Tellers, Thomas J. Tucker, Yu Yuan, Daniel Zewge
-
Patent number: 8541375Abstract: Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.Type: GrantFiled: December 16, 2011Date of Patent: September 24, 2013Assignee: Theravance, Inc.Inventor: Michael R. Leadbetter
-
Publication number: 20130244888Abstract: The invention provides nucleoside and nucleotide molecules containing cleavable linkers linking a label such as a dye. The invention also provides nucleosides and nucleotide molecules containing a blocking group, either removable or non-removable. The invention additionally provides methods of using the nucleoside and nucleotide molecules containing a cleavable linker and/or a blocking group.Type: ApplicationFiled: March 18, 2013Publication date: September 19, 2013Applicant: ILLUMINA, INC.Inventors: Chanfeng Zhao, Igor Kozlov, Melissa Won
-
Publication number: 20130243751Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.Type: ApplicationFiled: December 14, 2011Publication date: September 19, 2013Inventors: Armelle PHALIPON, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
-
Publication number: 20130244953Abstract: A delivery system is described that includes a polymer network that can incorporate a therapeutic peptide for targeted delivery to a cell, e.g., a cancer cell. The polymer network can secure the therapeutic peptide via two different mechanisms. First, a polymer of the network can interact with the therapeutic peptide via charge/charge interaction to form a complex with the peptide, thereby holding the peptide within the network. Second, the polymer network can be crosslinked, providing another level of securement for holding the therapeutic peptide within the network. The two levels of securement can be reversible, and following delivery of the network to the interior of a targeted cell reversal of the securement mechanisms can release the therapeutic peptide within the cell.Type: ApplicationFiled: September 11, 2012Publication date: September 19, 2013Inventors: Peisheng Xu, Bindu Thapa, Bei Cheng
-
Publication number: 20130230898Abstract: The invention relates to a method for the preparation of a hydroxyalkyl starch derivative which comprises reacting hydroxyalkyl starch (HAS) via the optionally oxidised reducing end of the HAS with the amino group M of a crosslinking compound which, apart from the amino group, comprises a specifically protected carbonyl group, namely an acetal group or a ketal group.Type: ApplicationFiled: February 19, 2013Publication date: September 5, 2013Applicant: Fresenius Kabi Deutschland GmbHInventors: Frank Hacket, Thomas Hey, Franziska Hauschild, Helmut Knoller, Martin Schimmel, Klaus Sommermeyer
-
Publication number: 20130224237Abstract: Compositions for inducing or enhancing antigenicity of a target cell by modulating the nonsense mediated decay pathway in the target cell. The compositions comprise one or more cell binding ligands providing specificity and delivery of an oligonucleotide or other molecule to the target. These compositions have broad applicability in the treatment of many diseases.Type: ApplicationFiled: July 20, 2011Publication date: August 29, 2013Applicant: UNIVERSITY OF MIAMIInventor: Eli Gilboa
-
Publication number: 20130216621Abstract: Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to about 500 nanometers. In some embodiments, the Signal-1 moiety and the Signal-2 moiety are bound to the same polymer carrier. Associated methods are also provided.Type: ApplicationFiled: December 21, 2012Publication date: August 22, 2013Inventors: Cory Berkland, Joshua Sestak, Teruna Siahaan
-
Publication number: 20130217027Abstract: Control agents for immuno-precipitation assays, methods of using the control agents and kits comprising the control agents are provided.Type: ApplicationFiled: March 29, 2013Publication date: August 22, 2013Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Bradley E. BERNSTEIN, Alon Goren
-
Publication number: 20130216600Abstract: The present invention provides antimicrobial nanoparticle conjugates and an efficient method of preparing same. In particular, the invention relates to the preparation of antifungal nanoparticle conjugates comprising amphotericin B covalently immobilized to nanoparticles. The conjugates, and suspensions thereof, can be used to form antifungal coatings with particular application to medical devices and materials.Type: ApplicationFiled: August 23, 2011Publication date: August 22, 2013Applicant: Matera LDAInventors: Lino Da Silva Ferreira, Cristiana Da Silva Oliveira Paulo
-
Patent number: 8513185Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: GrantFiled: October 13, 2010Date of Patent: August 20, 2013Inventor: Alexander B. Sigalov
-
Publication number: 20130210749Abstract: The invention provides novel peptides and constructs. In addition the invention provides methods for carrying compounds across the cell membrane, for antagonizing or destroying X-protein of HBV, treatment and/or management of HBV infection, treatment and/or prevention of HCC, and degradation of a target protein.Type: ApplicationFiled: June 10, 2011Publication date: August 15, 2013Applicant: Auckland Uniservices LimitedInventor: Geoffrey Wayne Krissansen
-
Publication number: 20130210724Abstract: Described herein are CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates. Also disclosed are methods of using (e.g., to treat a disorder) the CDP-therapeutic peptide conjugates, therapeutic delivery systems comprising CDP-therapeutic peptide conjugates, compositions comprising CDP-therapeutic peptide conjugates, dosage forms comprising CDP-therapeutic peptide conjugates, and kits comprising CDP-therapeutic peptide conjugates.Type: ApplicationFiled: April 12, 2013Publication date: August 15, 2013Applicant: Cerulean Pharma Inc.Inventor: Cerulean Pharma Inc.
-
Publication number: 20130203647Abstract: A composition comprises nanofibres for the delivery of a peptide across the blood brain barrier in a method of therapy of the human or animal body, wherein the nanofibres comprise a peptide conjugated to a lipophilic group. Further, a compound comprises a Dalargin or a derivative having one or more substituted, deleted or inserted aminoacyl units, and, conjugated to an aminoacyl group preferably via a side chain, a lipophilic group, optionally via a linker.Type: ApplicationFiled: July 11, 2011Publication date: August 8, 2013Applicant: UNIVERSITY COLLEGE LONDONInventors: Ijeoma Uchegbu, Andreas Schatzlein, Mariarosa Mazza
-
Publication number: 20130196930Abstract: Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: WYETH LLCInventor: WYETH LLC
-
Publication number: 20130195760Abstract: Chlorotoxin variants, chlorotoxin variant conjugates, compositions that include the chlorotoxin variants or conjugates, and methods for using the chlorotoxin variants, conjugates, and compositions.Type: ApplicationFiled: November 9, 2012Publication date: August 1, 2013Applicant: FRED HUTCHINSON CANCER RESEARCH CENTERInventor: Fred Hutchinson Cancer Research Center
-
Publication number: 20130195791Abstract: Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R? is derived from a compound comprising at least one reactive amide group, R? is derived from a compound comprising at least one reactive aminooxy group, and X is H, CnH(n+2) or other atoms. Additional methods are also provided.Type: ApplicationFiled: December 21, 2012Publication date: August 1, 2013Inventors: Cory Berkland, Joshua Sestak
-
Publication number: 20130196897Abstract: To develop glucosamine (GlcN) pro-drugs with properties superior to the presently available GlcN products, we have synthesized derivatives with improved pharmaceutical properties. The synthesized derivatives include peptide-GlcN ester and amide conjugates where the peptide portion consists of one or more amino acids. One such compound is (5-amino-3,4,6-trihydroxyoxan-2-yl)methyl 2-(2-aminoacetamido)-3-methylbutanoate or glycine-valine-COO-GlcN (GV-GlcN).Type: ApplicationFiled: September 19, 2012Publication date: August 1, 2013Inventors: Fahkreddin Jamali, Kamalijit Kaur, Mohammadhossien Gilzad
-
Publication number: 20130190246Abstract: This invention relates to collagen-binding synthetic peptidoglycans. More particularly, this invention relates to collagen-binding synthetic peptidoglycans for use in vascular intervention procedures. The invention also relates to kits comprising such collagen-binding synthetic peptidoglycans and catheters or stents.Type: ApplicationFiled: June 23, 2011Publication date: July 25, 2013Applicant: PURDUE RESEARCH FOUNDATIONInventors: John E. Paderi, Alyssa Panitch, Kinam Park, Katherine Stuart
-
Patent number: 8487075Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: February 7, 2012Date of Patent: July 16, 2013Assignee: The University of Utah Research FoundationInventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones
-
Patent number: 8481678Abstract: Peptide-based reagents comprising at least one tooth surface-binding peptide for delivery of at least one polymer-coated white colorant to the surface of teeth are provided. The peptide-based reagent may comprise at least one tooth-binding peptide coupled to, either directly or through one or more spacers, a polymer-binding peptide capable of binding to the polymeric coating on a polymer-coated white colorant. Methods of delivering a polymer-coated white colorant to a tooth surface are also provided as well as oral care compositions comprising the present peptide-based reagents. The peptide-based reagents may be used in conjunction with at least one polymer-coated white colorant to improve the cosmetic appearance of teeth.Type: GrantFiled: February 2, 2010Date of Patent: July 9, 2013Assignee: E I du Pont de Nemours and CompanyInventors: Douglas Robert Anton, Scott D. Cunningham, Stephen R. Fahnestock, Kari A. Fosser, Hong Wang
-
Publication number: 20130172230Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.Type: ApplicationFiled: September 14, 2012Publication date: July 4, 2013Applicants: Arbor Vita Corporation, NoNo Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Publication number: 20130171180Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, as well as to their process of preparation, their use in the peptide synthesis, said peptide and the use of said peptide.Type: ApplicationFiled: December 22, 2011Publication date: July 4, 2013Applicant: TFCHEMInventors: Geraldine Deliencourt-Godefroy, Hyacinthe Fillon, Thibaut Martin
-
Publication number: 20130172257Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: ApplicationFiled: June 29, 2012Publication date: July 4, 2013Applicant: Rani Therapeutics, LLCInventor: Mir Imran
-
Publication number: 20130172528Abstract: The invention provides methods for drying dalbavancin. The method includes providing wet dalbavancin that includes dalbavancin, water, and a solvent. The wet dalbavancin is dried at at a temperature of about 30° C. or less, at a vacuum pressure of about 50 mbar or less, until the water level of the wet dalbavancin is less than about 20% (w/w). Water is then added to the dalbavancin and the resulting wet dalbavancin is dried at least once more at a temperature of about 30° C. or less, at a vacuum pressure of about 50 mbar or less, until the solvent level of the dalbavancin is less than about 3.0% (w/w).Type: ApplicationFiled: August 3, 2012Publication date: July 4, 2013Inventor: MARTIN STOGNIEW
-
Publication number: 20130165391Abstract: Therapeutic peptides (and peptoids) for preventing or inhibiting tissue damage associated with ischemia and/or reperfusion are provided, along with peptides (and peptoids) for preventing or inhibiting cancerous tissue growth. The peptides are derived from ?2-glycoprotein I. Pharmaceutical and veterinary compositions comprising the peptides are also provided. Methods of using the peptides to prevent or inhibit tissue damage associated with ischemia and/or reperfusion and/or to prevent or inhibit tissue damage or the growth of cancerous tissue are also provided.Type: ApplicationFiled: March 1, 2013Publication date: June 27, 2013Applicant: KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventor: Kansas State University Research Foundation
-
Patent number: 8470967Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.Type: GrantFiled: September 26, 2011Date of Patent: June 25, 2013Assignee: Duke UniversityInventors: Ashutosh Chilkoti, Felipe Garcia Quiroz, Miriam Amiram
-
Publication number: 20130157961Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.Type: ApplicationFiled: April 28, 2011Publication date: June 20, 2013Applicant: ESPERANCE PHARMACEUTICALS, INC.Inventors: Hector Alila, Carola Leuschner, Martha Juban, Ann Coulter
-
Publication number: 20130149331Abstract: The present invention provides an immunogenic composition comprising a T-cell antigen in association with a rhamnose monosaccharide and/or Forssman disaccharide, and corresponding methods for inducing immune response. The T-cell antigen may be for example, a tumor vaccine, such as a tumor cell or one or more tumor antigens. The invention takes advantage of the naturally high titers of anti-Rhamnose and/or anti-Forssman disaccharide in humans to target vaccine compositions to antigen presenting cells.Type: ApplicationFiled: May 3, 2012Publication date: June 13, 2013Inventors: Peng George Wang, Wenlan Alex Chen, Brian Martin, Mario R. Mautino, Nicholas N. Vahanian, Charles J. Link, JR.
-
Publication number: 20130143821Abstract: Described herein are modified hyaluronans or the pharmaceutically-acceptable salt or ester thereof, wherein the modified hyaluronan comprises at least one hydrophobic polypeptide covalently bonded to hyaluronan. The modified hyaluronans can be used as viscosupplements in a number of medical applications. The modified hyaluronans can also be used in several biological and medical applications. Methods for preparing the modified hyaluronans are also provided herein.Type: ApplicationFiled: February 3, 2011Publication date: June 6, 2013Applicants: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Jules John Magda, Grant D. mith, Dmitry Bedrov, Jimmy W. Mays
-
Publication number: 20130137644Abstract: The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.Type: ApplicationFiled: October 24, 2012Publication date: May 30, 2013Applicant: CellectisInventor: Cellectis
-
Publication number: 20130137850Abstract: An objective of the invention is to provide an excellent biomaterial having a good operability and a high safety; the solution is a polymer having one or more peptide units represented by formula (1) as described below and one or more saccharide residues derived from polysaccharides: -(Pro-Y-Gly)n-??(1) wherein, Y represents Pro or Hyp and n is an integer of 1 or more; the invention provides a novel polymer having both various characteristics of a collagen-like polypeptide suitable for a biomaterial, and characteristics of polysaccharides, namely, a high hydrophilicity and enzymolytic degradation, and also having a high mechanical strength and water absorbing properties; furthermore, the water absorbing properties and enzymolysis properties of the resultant polymer can be controlled by changing an amount of charging the peptide oligomer and the polysaccharides in a condensation reaction.Type: ApplicationFiled: November 29, 2012Publication date: May 30, 2013Applicant: JNC CORPORATIONInventor: Jnc Corporation
-
Publication number: 20130136742Abstract: Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance.Type: ApplicationFiled: February 1, 2013Publication date: May 30, 2013Inventors: Kyunglim LEE, Youngjoo Kwon, Miyoung Kim, Moonhee Kim
-
Patent number: 8450441Abstract: A polymer containing an N-linked sialo-glycan wherein a sialo-glycan is condensed to a ?-polyglutamic acid using a chemical compound having an amino group on one end and a carboxyl group on another end and represented by the structural formula (I). Formula (I) (In the formula, Z means a hydroxy group or a residue represented by the formula (II), and n represents an integer of 10 or more, with the proviso that any one or more of the Z's is represented by the formula in (II).) Formula (II) (In the formula, X means a hydroxy group or an acetylamino group, Y1 and Y2 mean a hydroxyl group or an N-acetylneuraminic acid residue, L means a hydrocarbon, an m represents 0 or an integer of 1 or 2, with the proviso that Y1 and Y2 are not the same.Type: GrantFiled: June 24, 2008Date of Patent: May 28, 2013Assignees: National University Corporation Shizuoka University, Shizuoka Prefectural Universities Corporation, Yamasa CorporationInventors: Taiichi Usui, Takeomi Murata, Takashi Suzuki, Ilpal Jwa, Yusuke Ohba, Tomoki Hamamoto, Toshitada Noguchi
-
Publication number: 20130129665Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: ApplicationFiled: January 11, 2013Publication date: May 23, 2013Applicant: CERULEAN PHARMA INC.Inventor: Cerulean Pharma Inc.
-
Publication number: 20130131312Abstract: A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which the compound is intended to bind, and (b) conjugated to the compound, an arginine-rich peptide effective to enhance the uptake of the compound into target cells. The string of bases in the compound includes at least one inosine base positioned in the string so as to limit the number of contiguous guanine bases in said string to three or fewer. The conjugate has greater cellular uptake than the compound alone, by virtue of the arginine-rich peptide, and substantially greater antisense activity greater activity than the conjugate in the absence of inosine-for guanine substitutions.Type: ApplicationFiled: September 23, 2011Publication date: May 23, 2013Applicant: AVI BIOPHARMA, INC.Inventors: Patrick L. Iversen, Dwight D. Weller, Jed N. Hassinger
-
Publication number: 20130130370Abstract: The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.Type: ApplicationFiled: January 18, 2013Publication date: May 23, 2013Applicant: THE ROCKEFELLER UNIVERSITYInventor: The Rockefeller University
-
Publication number: 20130130969Abstract: The instant invention refers to an antibacterial peptide with all aminoacids in D-configuration, possessing strong antimicrobial activity against Gram-negative and Gram-positive bacteria and Candida strains. The peptide can be in linear form or multimerised on a skeleton of polyacrylamide, of dextrane units or on a skeleton of ethylene glycol units. The peptide is resistant to proteolysis especially when synthesized in the tetra-branched form where identical peptide sequences are linked together by an appropriate molecular scaffold.Type: ApplicationFiled: July 11, 2011Publication date: May 23, 2013Applicant: SETLANCE S.R.L.Inventors: Alessandro Pini, Chiara Falciani, Luisa Bracci
-
Publication number: 20130122043Abstract: The present invention provides modified multi-chain and multi-subunit proteins and methods for making them. In some protease embodiments the proteins are modified AB5 toxins in which a compound of interest is attached to the A1 chain.Type: ApplicationFiled: April 20, 2011Publication date: May 16, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Carla Guimaraes, Hidde Ploegh
-
Publication number: 20130115700Abstract: A method for transacting nucleic acid to cell comprising a step for forming a nucleic acid complex by bringing a double-stranded nucleic acid molecule into contact with a nucleic acid carrier having an amino acid sequence of alternating a basic amino acid and a hydrophobic amino acid, which has a peptide chain that forms a ?-sheet structure in which a side chain of a positively charged basic amino acid is disposed on one surface side and a side chain of a hydrophobic amino acid is disposed on the opposite surface side in the presence of the double-stranded nucleic acid molecule having a double helix structure, and by binding the double-stranded nucleic acid molecule and the peptide chain through either one or both of the electrostatic interaction between the side chains of the basic amino acid and phosphate groups and hydrogen bonds between the double stranded-nucleic acid molecule and the peptide chain and a nucleic acid complex used for the same are disclosed.Type: ApplicationFiled: July 7, 2011Publication date: May 9, 2013Applicant: KITAKYUSHU FOUNDATION FOR THE ADVANCEMENT OF INDUSTRY SCIENCE AND TECHNOLOGYInventor: Masayuki Fujii
-
Patent number: 8435491Abstract: A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed.Type: GrantFiled: May 13, 2010Date of Patent: May 7, 2013Assignee: Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: Mei-Hui Wang, Wuu-Jyh Lin, Chuan-Yi Chien, Hung-Man Yu, Reiko Takasaka Lee, Yuan-Chuan Lee
-
Publication number: 20130108662Abstract: A peptide having an amino acid sequence containing at least eight consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein. The peptide is suitable as a cell-penetrating peptide. A complex of the peptide and a cargo molecule non-covalently bound to the peptide. The cargo molecule may be a nucleic acid, an amino acid, a peptide, a protein, a carbohydrate, a lipid, or a small molecule. A method of penetrating or transfecting a cell using the complex.Type: ApplicationFiled: July 25, 2012Publication date: May 2, 2013Applicant: Evonik Roehm GmbHInventors: Roland Brock, Rainer Fischer, Mariola Fotin-Mleczek, Hansjoerg Hufnagel, Norbert Windhab
-
Patent number: 8431527Abstract: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins) Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3DG.Type: GrantFiled: October 25, 2010Date of Patent: April 30, 2013Assignee: Fox Chase Cancer CenterInventors: Truman R. Brown, Francis Kappler
-
Publication number: 20130102049Abstract: Novel method and reagents for generating reversibly tagged saccharides, aldehydes, carboxyl acids, or orthoacetates useful in analytical and diagnostic applications are disclosed. Saccharides are coupled at the reducing end to tagging moieties comprising a reagent selected from a ortho-diaminobenzoic(DAB)-peptide, an aldo-imidazole or N-methylated aldo-imidazole, or an ortho-phenyldiamine (OPD) or substituted OPD. The tagged saccharide further comprising detectable or functional groups coupled to the tagging moiety are provided. Kits and reagents for chromatography and mass spectrometry are disclosed.Type: ApplicationFiled: July 12, 2012Publication date: April 25, 2013Applicant: ACADEMIA SINICAInventor: Wen-Bin YANG
-
Publication number: 20130096072Abstract: Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides.Type: ApplicationFiled: October 12, 2012Publication date: April 18, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Publication number: 20130095173Abstract: Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated.Type: ApplicationFiled: June 10, 2011Publication date: April 18, 2013Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Govind Ragupathi, Philip O. Livingston, Jianglong Zhu, Karthik Iyer, Guangbin Yang
-
Publication number: 20130096275Abstract: Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed.Type: ApplicationFiled: December 4, 2012Publication date: April 18, 2013Applicant: Abbott LaboratoriesInventor: Abbott Laboratories
-
Publication number: 20130096049Abstract: The invention concerns a novel antimicrobial peptide (AMP) polymer conjugate comprising at least one AMP, typically colistin, and a dextrin polymer wherein said dextrin polymer has a molecular weight between 5,000-60,000 g/mol and is modified by the additions of pendant groups which increase the stability of the conjugate and so delays its degradation thereby slowing the rate at which the AMP is released.Type: ApplicationFiled: June 1, 2011Publication date: April 18, 2013Applicant: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITEDInventors: Elaine Ferguson, David Thomas, Timothy Walsh